Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving eribulin mesylate and carboplatin together before
surgery works in treating patients with stage I-III triple-negative breast cancer. Drugs used
in chemotherapy, such as eribulin mesylate and carboplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal
tissue that needs to be removed.